Wells Fargo & Company Viracta Therapeutics, Inc. Put Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding VIRX
# of Institutions
44Shares Held
9.03MCall Options Held
10.9KPut Options Held
400-
Bvf Inc San Francisco, CA3.61MShares$795,2250.06% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$334,4520.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.16MShares$255,4810.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$151,7350.19% of portfolio
-
Laurion Capital Management LP New York, NY407KShares$89,6050.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $8.26M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...